MX2009006310A - Composiciones y metodos para tratar trastornos musculares y cardiovasculares. - Google Patents

Composiciones y metodos para tratar trastornos musculares y cardiovasculares.

Info

Publication number
MX2009006310A
MX2009006310A MX2009006310A MX2009006310A MX2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A MX 2009006310 A MX2009006310 A MX 2009006310A
Authority
MX
Mexico
Prior art keywords
cardiovascular disorders
compositions
methods
muscular
treat muscular
Prior art date
Application number
MX2009006310A
Other languages
English (en)
Inventor
Jan Weiler
Jonathan Hall
Iwan Beuvink
Matthias Mueller
Martina Schinke-Braun
Fabrizio Serluca
Christian Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009006310A publication Critical patent/MX2009006310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Abstract

La presente invención se refiere a un novedoso microARN, mir 208-2, implicado en los trastornos musculares y cardiovasculares. La presente invención también se refiere a agentes terapéuticos de oligonucleótidos (oligonucleótidos anti-sentido y/u oligonucleótidos de doble cadena, tales como dsARN), y a su uso en el tratamiento de trastornos musculares y cardiovasculares resultantes de la desregulación de mir-208-2.
MX2009006310A 2006-12-14 2007-12-13 Composiciones y metodos para tratar trastornos musculares y cardiovasculares. MX2009006310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86993706P 2006-12-14 2006-12-14
PCT/US2007/025535 WO2008076324A2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Publications (1)

Publication Number Publication Date
MX2009006310A true MX2009006310A (es) 2009-07-22

Family

ID=39536897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006310A MX2009006310A (es) 2006-12-14 2007-12-13 Composiciones y metodos para tratar trastornos musculares y cardiovasculares.

Country Status (11)

Country Link
US (3) US20100280094A1 (es)
EP (1) EP2104733A2 (es)
JP (3) JP2010512747A (es)
KR (1) KR20090098818A (es)
CN (2) CN102604951A (es)
AU (1) AU2007334502B2 (es)
BR (1) BRPI0719995A2 (es)
CA (1) CA2672606A1 (es)
EA (2) EA201101361A1 (es)
MX (1) MX2009006310A (es)
WO (1) WO2008076324A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2056882T3 (pl) 2006-08-01 2013-03-29 Univ Texas Identyfikacja mikro-RNA, który aktywuje ekspresję łańcucha ciężkiego beta-miozyny
MX2010001216A (es) 2007-07-31 2010-04-30 Univ Texas Microarn que controla la expresion de miosina y la identidad de miofibras.
US8629119B2 (en) * 2009-02-04 2014-01-14 The Board Of Regents, The University Of Texas System Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
EP2703501A1 (en) 2009-03-12 2014-03-05 Brandeis University Reagents and Methods for PCR
AU2011343720A1 (en) 2010-12-15 2013-04-11 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
BR112015008399A8 (pt) 2012-10-15 2017-10-03 Ionis Pharmaceuticals Inc Composto para modular a expressão de c90rf72, seu uso, oligonucleotídeo modificado, composto de fita dupla e composição
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
WO2014169126A1 (en) * 2013-04-10 2014-10-16 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
MY192689A (en) 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US9752144B2 (en) * 2014-08-04 2017-09-05 MiRagen Therapeutics, Inc. Inhibitors of MYH7B and uses thereof
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
PL3283080T3 (pl) 2015-04-16 2020-07-27 Ionis Pharmaceuticals, Inc. Kompozycja do modulowania ekspresji c9orf72
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CN106148519A (zh) * 2016-07-05 2016-11-23 无锡市第二人民医院 一种microRNA‑499的快速检测方法
US20230107117A1 (en) * 2017-08-10 2023-04-06 City Of Hope CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY
KR102281710B1 (ko) 2021-02-19 2021-07-28 조기정 에어튜브를 이용한 선박 안전장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
WO1992002534A2 (en) * 1990-08-03 1992-02-20 Sterling Drug, Inc. Compounds and methods for inhibiting gene expression
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JP3516167B2 (ja) * 1992-12-08 2004-04-05 ローム株式会社 タンタルコンデンサチップの製造方法
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7521184B2 (en) * 2003-08-22 2009-04-21 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
EP1877557A2 (en) * 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
JP2009523013A (ja) * 2006-01-10 2009-06-18 コニンクリユケ ネーデルランドセ アカデミ ファン ウェテンスハッペン 新規な核酸分子及びそのコレクション、並びにそれらの用途及び同定方法
PL2056882T3 (pl) * 2006-08-01 2013-03-29 Univ Texas Identyfikacja mikro-RNA, który aktywuje ekspresję łańcucha ciężkiego beta-miozyny
MX2010001216A (es) * 2007-07-31 2010-04-30 Univ Texas Microarn que controla la expresion de miosina y la identidad de miofibras.

Also Published As

Publication number Publication date
AU2007334502A1 (en) 2008-06-26
CN102604951A (zh) 2012-07-25
US20120114744A1 (en) 2012-05-10
EA200900782A1 (ru) 2009-12-30
AU2007334502B2 (en) 2011-12-15
BRPI0719995A2 (pt) 2014-03-18
JP2012131812A (ja) 2012-07-12
JP2010512747A (ja) 2010-04-30
US20100280094A1 (en) 2010-11-04
EP2104733A2 (en) 2009-09-30
WO2008076324A3 (en) 2009-04-09
KR20090098818A (ko) 2009-09-17
EA201101361A1 (ru) 2012-11-30
US20120041052A1 (en) 2012-02-16
WO2008076324A2 (en) 2008-06-26
JP2012019789A (ja) 2012-02-02
CA2672606A1 (en) 2008-06-26
CN101563458A (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
MX2009006310A (es) Composiciones y metodos para tratar trastornos musculares y cardiovasculares.
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010017152A3 (en) Modulation of toll-like receptor 8 expression by antisense oligonucleotides
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TW200637522A (en) Skin treatment articles and methods
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2008104978A3 (en) Novel sirna structures
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2008141308A3 (en) Gene expression and pain
GB0625648D0 (en) Compounds
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2010102058A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2010017154A3 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2010014572A3 (en) Modulation of toll-like receptor 9 expression by antisense oligonucleotides
WO2011031482A3 (en) Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal